
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

SCHEDULE 13D

**Under the Securities Exchange Act of 1934
(Amendment No. 4)***

INTERPACE BIOSCIENCES, INC.
(Name of Issuer)

Common Stock
(Title of Class of Securities)

46062X303
(CUSIP Number)

**Ampersand 2018 Limited Partnership
AMP-18 Management Company Limited Partnership
AMP-18 MC LLC
55 William Street, Suite 240
Wellesley, MA 02481
Telephone: (781) 239-0700**
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

May 10, 2021
(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of § 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1	NAME OF REPORTING PERSONS Ampersand 2018 Limited Partnership	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) <input type="checkbox"/> (b) <input type="checkbox"/>	
3	SEC USE ONLY	
4	SOURCE OF FUNDS (See Instructions) AF	
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) <input type="checkbox"/>	
6	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER 0
	8	SHARED VOTING POWER 4,666,666 (1)
	9	SOLE DISPOSITIVE POWER 0
	10	SHARED DISPOSITIVE POWER 4,666,666 (1)
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,666,666 (1)	
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) <input type="checkbox"/>	
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 39.1% (2)	
14	TYPE OF REPORTING PERSON (See Instructions) IV	

- (1) Evidenced by 28,000 shares of Series B Convertible Preferred Stock, par value \$0.01 per share (the "Series B"), of Interpace Biosciences, Inc. (the "Issuer"). The Series B is convertible from time to time, at the option of the holder thereof, into a number of shares of common stock, par value \$0.01 per share, of the Issuer (the "Common Stock"), equal to the initial stated value per Series B share of \$1,000 divided by an initial conversion price of \$6.00 per share and then multiplied by the number of shares of Series B to be converted.
- (2) This percentage (a) is calculated based upon 4,112,843 shares of Common Stock outstanding as of April 30, 2021, as disclosed in the Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2021 filed by the Issuer on May 11, 2021 and (b) assumes the conversion of all 47,000 outstanding shares of Series B into an aggregate of 7,833,334 shares of Common Stock.

1	NAME OF REPORTING PERSONS AMP-18 Management Company Limited Partnership		
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) <input type="checkbox"/> (b) <input type="checkbox"/>		
3	SEC USE ONLY		
4	SOURCE OF FUNDS (See Instructions) AF		
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) <input type="checkbox"/>		
6	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware		
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER 0	
	8	SHARED VOTING POWER 4,666,666 (1)	
	9	SOLE DISPOSITIVE POWER 0	
	10	SHARED DISPOSITIVE POWER 4,666,666 (1)	
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,666,666 (1)		
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) <input type="checkbox"/>		
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 39.1% (2)		
14	TYPE OF REPORTING PERSON (See Instructions) IA		

- (1) Evidenced by 28,000 shares of Series B. The Series B is convertible from time to time, at the option of the holder thereof, into a number of shares of Common Stock equal to the initial stated value per Series B share of \$1,000 divided by an initial conversion price of \$6.00 per share and then multiplied by the number of shares of Series B to be converted.
- (2) This percentage (a) is calculated based upon 4,112,843 shares of Common Stock outstanding as of April 30, 2021, as disclosed in the Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2021 filed by the Issuer on May 11, 2021 and (b) assumes the conversion of all 47,000 outstanding shares of Series B into an aggregate of 7,833,334 shares of Common Stock.

1	NAME OF REPORTING PERSONS AMP-18 MC LLC		
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) <input type="checkbox"/> (b) <input type="checkbox"/>		
3	SEC USE ONLY		
4	SOURCE OF FUNDS (See Instructions) AF		
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) <input type="checkbox"/>		
6	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware		
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER 0	
	8	SHARED VOTING POWER 4,666,666 (1)	
	9	SOLE DISPOSITIVE POWER 0	
	10	SHARED DISPOSITIVE POWER 4,666,666 (1)	
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,666,666 (1)		
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) <input type="checkbox"/>		
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 39.1% (2)		
14	TYPE OF REPORTING PERSON (See Instructions) IA		

- (1) Evidenced by 28,000 shares of Series B. The Series B is convertible from time to time, at the option of the holder thereof, into a number of shares of Common Stock equal to the initial stated value per Series B share of \$1,000 divided by an initial conversion price of \$6.00 per share and then multiplied by the number of shares of Series B to be converted.
- (2) This percentage (a) is calculated based upon 4,112,843 shares of Common Stock outstanding as of April 30, 2021, as disclosed in the Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2021 filed by the Issuer on May 11, 2021 and (b) assumes the conversion of all 47,000 outstanding shares of Series B into an aggregate of 7,833,334 shares of Common Stock.

Item 1. Security and Issuer

This Amendment No. 4 to Schedule 13D (this “Amendment No. 4”) supplements and amends the Schedule 13D originally filed with the Securities and Exchange Commission (the “SEC”) on July 25, 2019, as amended by Amendment No. 1 thereto, filed with the SEC on January 17, 2020, as amended by Amendment No. 2 thereto, filed with the SEC on April 23, 2020, and as amended by Amendment No. 3 thereto, filed with the SEC on January 19, 2021 (as so amended, the “Prior Statement” and, as supplemented and amended by this Amendment No. 4, the “Statement”). Capitalized terms used but not otherwise defined herein have the meanings set forth in the Prior Statement. Except as specifically supplemented and amended by this Amendment No. 4, items in the Prior Statement remain unchanged.

This Amendment No. 4 is being filed to report that, on May 10, 2021, the Issuer and Ampersand 2018 Limited Partnership, a Delaware limited partnership (“Ampersand”) entered into an amendment to the Secured Promissory Note, dated January 7, 2021 (the “Note”) and an amendment to the related Security Agreement, dated January 7, 2021 (the “Security Agreement”) as further discussed below under Item 6.

Item 6. Contracts, Arrangements, Understandings or Relationship with Respect to Securities of the Issuer

Item 6 of the Prior Statement is hereby amended and supplemented to include the following:

The Support Agreement (as defined in the Prior Statement) was terminated on September 30, 2020 pursuant to a termination agreement, dated July 9, 2020, between the Issuer and Ampersand.

On January 7, 2021, the Issuer entered into the Note with Ampersand pursuant to which Ampersand made a loan to the Issuer in an aggregate principal amount equal to \$3,000,000. The rate of interest on the Note is equal to eight percent (8.0%) per annum and its maturity date is the earlier of (a) June 30, 2021 and (b) the date on which all amounts become due upon the occurrence of any event of default as defined in the Note. No interest payments are due on the Note until its maturity date. On May 10, 2021, the Issuer entered into an amendment to the Note with Ampersand to increase the aggregate principal amount of the Note to \$4,500,000.

Pursuant to the Security Agreement, the Note is secured by a first priority lien and security interest on substantially all of the assets of the Issuer. Additionally, if a change of control of the Issuer occurs (as defined in the Note) the Issuer is required to make a prepayment of the Note in an amount equal to the unpaid principal amount, all accrued and unpaid interest, and all other amounts payable under the Note out of the net cash proceeds received by the Issuer from the consummation of the transactions related to such change of control. The Issuer may prepay the Note in whole or in part at any time or from time to time without penalty or premium by paying the principal amount to be prepaid together with accrued interest thereon to the date of prepayment. No prepaid amount may be re-borrowed.

The Note contains certain negative covenants which prevent the Issuer from issuing any debt securities pursuant to which the Issuer issues shares, warrants or any other convertible security in the same transaction or a series of related transactions, except that Issuer may incur or enter into any capitalized and operating leases in the ordinary course of business consistent with past practice, or borrowed money or funded debt in an amount not to exceed \$4.5 million (the “Debt Threshold”) that is subordinated to the Note on terms acceptable to Ampersand; provided, that if the aggregate consolidated revenue recognized by the Issuer as reported on Form 10-K as filed with the SEC for any fiscal year ending after January 10, 2020 exceeds \$45 million dollars, the Debt Threshold for the following fiscal year shall increase to an amount equal to: (x) ten percent (10%); multiplied by (y) the consolidated revenue as reported by the Issuer on Form 10-K as filed with the SEC for the previous fiscal year.

The foregoing descriptions of the Note, the Security Agreement, the amendment to the Note and the amendment to the Security Agreement are qualified in their entirety by reference to the full text of the Note, the Security Agreement, the amendment to the Note and the amendment to the Security Agreement, which are filed as Exhibits 2, 3, 4 and 5 to this Amendment No. 4, respectively, and are incorporated herein by reference in their entirety.

Item 7. Materials to Be Filed as Exhibits

Exhibit	Description
1.	<u>Joint Filing Agreement among Ampersand, AMCLP and AMCLLC (incorporated by reference to Exhibit 1 to the Schedule 13D filed by Ampersand 2018 Limited Partnership on July 25, 2019).</u>
2.	<u>Secured Promissory Note, dated January 7, 2021, by Interpace Biosciences, Inc. in favor of Ampersand 2018 Limited Partnership (incorporated by reference to Exhibit 2 to Amendment No. 3 to Schedule 13D filed by Ampersand 2018 Limited Partnership on January 19, 2021).</u>
3.	<u>Security Agreement, dated January 7, 2021, by and between Ampersand 2018 Limited Partnership and Interpace Biosciences, Inc. (incorporated by reference to Exhibit 3 to Amendment No. 3 to Schedule 13D filed by Ampersand 2018 Limited Partnership on January 19, 2021).</u>
4.	<u>Amendment to Secured Promissory Note, dated May 10, 2021, by and between Interpace Biosciences, Inc. and Ampersand 2018 Limited Partnership.</u>
5.	<u>Amendment to the Security Agreement, dated May 10, 2021, by and between Ampersand 2018 Limited Partnership and Interpace Biosciences, Inc.</u>

SIGNATURE

After reasonable inquiry and to the best of each of the undersigned's knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: May 18, 2021

Ampersand 2018 Limited Partnership

By: AMP-18 Management Company Limited Partnership, its
General Partner

By: AMP-18 MC LLC, its General Partner

By: /s/ Dana L. Niles

Name: Dana L. Niles

Title: Chief Operating Officer

AMP-18 Management Company Limited Partnership

By: AMP-18 MC LLC, its General Partner

By: /s/ Dana L. Niles

Name: Dana L. Niles

Title: Chief Operating Officer

AMP-18 MC LLC

By: /s/ Dana L. Niles

Name: Dana L. Niles

Title: Chief Operating Officer

**AMENDMENT TO
SECURED PROMISSORY NOTE**

This Amendment to Secured Promissory Note (this “**Amendment**”) is made and entered into as of May 10, 2021 (the “**Amendment Effective Date**”) by and between Interpace Biosciences, Inc., a Delaware corporation (the “**Borrower**”), and Ampersand 2018 Limited Partnership, a Delaware limited partnership (the “**Noteholder**”). Capitalized terms used herein but not otherwise defined shall have the respective meanings given to them in the Note (as defined below).

WHEREAS, the Borrower has entered into that certain Secured Promissory Note dated as of January 7, 2021 (the “**Note**”), made in favor of the Noteholder, in the aggregate principal amount of \$3,000,000.00 (the “**Original Amount**”);

WHEREAS, pursuant to Section 12.11 of the Note, any term of the Note may be amended or modified with the written consent of the Borrower and the Noteholder; and

WHEREAS, the Borrower and Noteholder desire to amend the Note to increase the aggregate principal amount of the Original Amount by \$1,500,000.00 (the “**Additional Amount**”) as further described herein.

NOW, THEREFORE, in accordance with the foregoing and intending to be legally bound hereby, the Borrower and the Noteholder hereby amend the Note as provided for below, and otherwise further agree as follows:

1. Amendment to the Note. The Note is hereby amended as follows:

(a) The principal amount as stated on the first page of the Note underneath the heading “Secured Promissory Note” is hereby amended by (i) deleting the word “\$3,000,000.00” and (ii) adding the word “\$4,500,000.00” in its place;

(b) The principal amount as stated in the first clause of the Note is hereby amended by (i) deleting the word “\$3,000,000.00” and (ii) adding the word “\$4,500,000.00” in its place;

(c) The defined term “Loan” is hereby amended by (i) deleting the word “\$3,000,000.00” and (ii) adding the word “\$4,500,000.00” in its place;

(d) The defined term “Pari Passu Note” is hereby amended and restated in its entirety as follows:

“**Pari Passu Note**” means that certain Secured Promissory Note dated the date hereof, as amended by that certain Amendment to Secured Promissory Note dated as of May 10, 2021, made by Borrower in favor of the Pari Passu Noteholder in the aggregate principal amount equal to \$3,000,000.00.

(e) The defined term “Security Agreement” is hereby amended and restated in its entirety as follows:

“**Security Agreement**” means the Security Agreement, dated as of the date hereof, as amended by that certain Amendment to Security Agreement dated as of May 10, 2021, by and between the Borrower and Noteholder.

(f) Section 5.1 of the Note is hereby amended and restated in its entirety as follows:

5.1 Interest Rate.

(a) Except as otherwise provided herein, (i) the outstanding principal amount of the Original Amount of the Loan made hereunder shall bear interest at the Applicable Rate commencing January 7, 2021, and (ii) the outstanding principal amount of the Additional Amount of the Loan made hereunder shall bear interest at the Applicable Rate commencing on the Amendment Effective Date.

(b) Interest on the outstanding principal amount of the Loan shall accrue in accordance with the terms of Section 5.1(a) until the Loan is paid in full, whether at maturity, upon acceleration, by prepayment, or otherwise.

2. Continued Effectiveness. Except as amended hereby, the Note shall remain in full force and effect and all of the rights and obligations under the Note are hereby affirmed. In the event of a conflict between the Note and this Amendment, this Amendment shall control.

3. References. From and after the Amendment Effective Date, any reference to the Note contained in any notice, request, certificate or other instrument, document or agreement executed concurrently with or after the execution and delivery of this Amendment shall be deemed to include this Amendment unless the context shall so otherwise require.

4. Counterparts. This Amendment may be signed in two or more counterparts (including by means of telecopied signature pages) any one of which need not contain the signature of more than one party, but all such counterparts taken together shall constitute one and the same agreement.

[remainder of page intentionally left blank]

IN WITNESS WHEREOF, the Parties have executed this Amendment as of the date first above written.

INTERPACE BIOSCIENCES, INC.

By /s/ Thomas W. Burnell

Name: Thomas W. Burnell

Title: President and CEO

**AMPERSAND 2018 LIMITED
PARTNERSHIP**

By: AMP-18 Management Company Limited
Partnership, its General Partner

By: AMP-18 MC LLC, its General Partner

By /s/ Herbert H. Hooper

Name: Herbert H. Hooper

Title: Managing Member

[Signature Page to Amendment to Secured Promissory Note]

**AMENDMENT TO
SECURITY AGREEMENT**

This Amendment to Security Agreement (this “**Amendment**”) is made and entered into as of May 10, 2021 (the “**Effective Date**”) by and between Interpace Biosciences, Inc., a Delaware corporation (the “**Grantor**”), and Ampersand 2018 Limited Partnership, a Delaware limited partnership in its capacity as collateral agent pursuant to the Notes (as hereinafter defined), as secured party (in such capacity, the “**Secured Party**”). Capitalized terms used herein but not otherwise defined shall have the respective meanings given to them in the Notes.

WHEREAS, the Secured Party has made a loan to the Grantor in an aggregate unpaid principal amount equal to \$3,000,000.00 (the “**Ampersand Loan**”), evidenced by that certain Secured Promissory Note dated as of January 7, 2021 (as amended, supplemented or otherwise modified from time to time, the “**Ampersand Note**”), made by the Grantor and payable to the order of the Secured Party;

WHEREAS, as of the Effective Date, the Secured Party and the Grantor have entered into that certain Amendment to Secured Promissory Note (the “**Ampersand Amendment**”) to increase the aggregate principal amount of the Ampersand Loan by \$1,500,000.00;

WHEREAS, 1315 Capital II, L.P., a Delaware limited partnership (“**1315 Capital**”), has made a loan to the Grantor in an aggregate unpaid principal amount equal to \$2,000,000.00 (the “**1315 Loan**” and together with the Ampersand Loan, the “**Loans**”), evidenced by that certain Secured Promissory Note dated as of January 7, 2021 (as amended, supplemented or otherwise modified from time to time, the “**1315 Note**” and together with the Ampersand Note, the “**Notes**”) made by the Grantor and payable to the order of 1315 Capital;

WHEREAS, as of the Effective Date, 1315 Capital and the Grantor have entered into that certain Amendment to Secured Promissory Note (the “**1315 Capital Amendment**”) to increase the aggregate principal amount of the 1315 Capital Loan by \$1,000,000.00;

WHEREAS, the Grantor has entered into that certain Security Agreement dated as of January 7, 2021 (the “**Security Agreement**”), made in favor of the Secured Party to secure the payment and performance of the Secured Obligations;

WHEREAS, pursuant to Section 14 of the Security Agreement, any term of the Security Agreement may be amended or modified with the written consent of the Grantor and the Secured Party; and

WHEREAS, the Grantor and the Secured Party desire to amend the Security Agreement to reflect the Ampersand Amendment and the 1315 Capital Amendment as further described herein.

NOW, THEREFORE, in accordance with the foregoing and intending to be legally bound hereby, the Grantor and the Secured Party hereby amend the Security Agreement as provided for below, and otherwise further agree as follows:

1. Amendment to the Security Agreement. The first “WHEREAS” clause of the Security Agreement is hereby amended and restated in its entirety as follows:

WHEREAS, on January 7, 2021, the Secured Party has made a loan to the Grantor (the “**Ampersand Loan**”), evidenced by that certain Secured Promissory Note of even date herewith, as amended by that certain Amendment to Secured Promissory dated as of May 10, 2021 (as amended, supplemented or otherwise modified from time to time, the “**Ampersand Note**”) in an aggregate unpaid principal amount equal to \$4,500,000.00, made by the Grantor and payable to the order of the Secured Party, and 1315 Capital II, L.P., a Delaware limited partnership (“**1315 Capital**”) has made a loan to the Grantor (the “**1315 Loan**” and together with the Ampersand Loan, the “**Loans**”), evidenced by that certain Secured Promissory Note of even date herewith, as amended by that certain Amendment to Secured Promissory Note dated as of May 10, 2021 (as amended, supplemented or otherwise modified from time to time, the “**1315 Note**” and together with the Ampersand Note, the “**Notes**”) in an aggregate unpaid principal amount equal to \$3,000,000.00, made by the Grantor and payable to the order of 1315 Capital. Capitalized terms used but not otherwise defined herein shall have the meanings assigned to such terms in the Notes;

2. Continued Effectiveness. Except as amended hereby, the Security Agreement shall remain in full force and effect and all of the rights and obligations under the Security Agreement are hereby affirmed. In the event of a conflict between the Security Agreement and this Amendment, this Amendment shall control.

3. References. From and after the Effective Date, any reference to the Security Agreement contained in any notice, request, certificate or other instrument, document or agreement executed concurrently with or after the execution and delivery of this Amendment shall be deemed to include this Amendment unless the context shall so otherwise require.

4. Counterparts. This Amendment may be signed in two or more counterparts (including by means of telecopied signature pages) any one of which need not contain the signature of more than one party, but all such counterparts taken together shall constitute one and the same agreement.

[remainder of page intentionally left blank]

IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first above written.

INTERPACE BIOSCIENCES, INC.

By /s/ Thomas W. Burnell

Name: Thomas W. Burnell

Title: President and CEO

**AMPERSAND 2018 LIMITED
PARTNERSHIP**

By: AMP-18 Management Company Limited
Partnership, its General Partner

By: AMP-18 MC LLC, its General Partner

By /s/ Herbert H. Hooper

Name: Herbert H. Hooper

Title: Managing Member

[Signature Page to Amendment to Security Agreement]